Advances in Bone Marrow Transplantation
such as high-dose post-transplantation cyclophosphamid, is a viable alternative for patients lacking HLA-matched donors. Actually many strategies for GVHD prophylaxis are in course in many preclinical
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
such as high-dose post-transplantation cyclophosphamid, is a viable alternative for patients lacking HLA-matched donors. Actually many strategies for GVHD prophylaxis are in course in many preclinical
acute GVHD. Unexpectedly, severe refractory acute GVHD can occur even in allo-HSCT from HLA matched sibling donor. The first line therapy for severe acute GVHD is corticosteroid
year old African American male with Acute Myeloid Leukemia who underwent human leucocyte antigen (HLA) matched sibling allogeneic peripheral blood SCT. His post transplant course was complicated by development
note that a significant population of patients, specifically minority groups, lack a suitable HLA-matched bone marrow, or peripheral stem cell donor, consequently UCB is able to fill this
often associated with significant morbidity. Allogeneic BMT, particularly if an HLA-matched sibling donor is available should be considered in patients with CGD who suffer from significant GI involvement
important alternative source of Hematopoietic Stem Cells (HSC) for allogeneic transplantation when suitable HLA-matched donors are unavailable. Cord Blood (CB) offers many benefits including rapid availability, absence…
cell lines specific for these phosphopeptides recognize and kill both leukemia cell lines and HLA-matched primary leukemia cells ex vivo . Central memory recall responses to phosphopeptide antigens is absent
complication of hematopoietic stem-cell transplant with reported incidence of 30% to 50% in HLA-match recipients and up to 50%-70% in unmatched recipients. GVHD can also be seen
cells CD8+/INFγ+, and specific cytotoxicity, in samples obtained from a cohort of 30 HLA-matched unrelated or haploidentical stem cell donors, divided into three groups, according to BKV positivity
translocation, but also the diagnosis of a monogenic diseased state as well as HLA matching, from a single cell [1] - an exciting prospect indeed
groups. There were only two UCB units matching a single API haplotype (HLA-A*30:01, -B*13:02, -C*06:02, DRB1*07:01, DQB1 ... there was only a single UCB donation with a HLA-A, -B, -C match for the top API haplotype…
cell transplantation is now being the emergent methodology for leukemia treatment. Due to HLA mis-match, there is chance of transplantation related mortality. However, with the increase in HLA
important in this context for assuring the survival of a graft. HLA ‘Epitope Matching’ is another concern in transplantation immunology which is generally addressed by tissue typing. Allelic difference, binding…
acute or acute allograft rejection. In order to select recipients without donor-specific anti- HLA antibodies the complement-dependent cytotoxicity crossmatch assay (CDC-CM) was established as standard procedure more…
used to supplement cross-match testing with cytotoxic analysis. However, the development of solid-phase single-bead antigen testing of solubilized human leukocyte antigens (HLA) to detect donor-specific antibodies…
cannot regenerate spontaneously, diseases involving the heart valves frequently necessitate surgical replacement without HLA/ABO matching and/or immunosuppression of the recipient with no cases of valve dysfunction or…
antigens and the absence of HLA-DR expression, a complete or high HLA profile match for allogenic use is not necessary, which permits to greatly enlarge the number of available
antigens and the absence of HLA-DR expression, a complete or high HLA profile match for allogenic use is not necessary, which permits to greatly enlarge the number of available
Eplet matching has been a great part globally. The analysis of eplet matching after pinpointing the HLA ID of both donor and recipient are performed molecularly as well as computationally ... predict the outcome of less…
allele has the closest match with HLA-A*33:03:01:01, except for a mismatch at position 270 in Exon 2. Instead of the expected
negative. All laboratory tests with the patient. Diagnosis:kidney donor. Recommendation: HLA study ,cross match, preparing for kidney donor
renal transplant, recipient reported to emergency without any details of donor recipient workup, HLA typing, cross matching & induction therapy or surgery, Underwent through a stormy course of events. Atypical haemolytic
Preoperative extensive work up for both the donor and recipient was performed including HLA typing, cross matching and CT angiogram for evaluation of donor kidney vasculature . All of our patients
false-positive” outcomes of the CDC-crossmatch. As methodical alternatives for anti-HLA antibody specific cross-matching two ELISA-based procedures i) the Antibody Monitoring System (AMS-) ELISA ... software, however…
most polymorphic regions in the human genome. Prior knowledge of HLA allelic polymorphisms is clinically important for matching donor and recipient during organ/tissue transplantation. HLA allelic information is also
For authors and organisers
Find the right journal for your paper and submit your manuscript.